Humboldt Fund focuses exclusively on synthetic biology as a general-purpose technology to remake chemicals, materials, foods, and medicines, led by a UCSF-trained PhD cell biologist who brings deep research background directly into fund leadership. The fund backs "bio revolution" companies that replace conventional industrial inputs with biology-based alternatives through a concentrated portfolio of category-defining names like Geltor, NotCo, Meatable, and MycoWorks, while investing globally across Latin America and Europe rather than maintaining a US-centric focus.